NEW YORK (GenomeWeb News) – Drug firm Summit and the Children's National Medical Center in Washington today announced a collaboration for the development of a proteomic assay to measure biomarkers in support of Summit's candidate drug for Duchenne Muscular Dystrophy (DMD).

Under the terms of the deal, Yetrib Hathout, a principal investigator at CNMC's Center for Genetic Medicine Research, will develop a mass spectrometry-based assay to measure levels of a protein called utrophin in DMD muscle that may prove useful in treating the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.